DIVERSA Technologies will be attending the Biospain 2026 conference in Bilbao from September 29 to October 1.

Our drug delivery technology based on lipidic nanoemulsions allows for safe and physiological intracellular delivery of complex macromolecules (peptides, proteins and nucleic acids) and small hydrophobic molecules. The platform has broad and fresh IP protection and is fully scalable and regulatory compliant. At DIVERSA, we want to bridge the gap between molecules and patients, between drug discovery and clinical application. We want to create new opportunities to improve patients' quality of life. Despite the discovery of many new targets and therapeutic molecules in labs around the world, less than 3% of them will make it to clinical stages. Most of these new molecules are discarded in the early stages of research, mostly because they cannot access the interior of the cell, where 3 out of 4 new molecules have their targets. We want change that. We want to spearhead the therapeutic revolution.

Founded 2022